Literature DB >> 24095280

Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.

Che-Hung Shen1, Ping Yuan, Rolando Perez-Lorenzo, Yaqing Zhang, Sze Xian Lee, Yang Ou, John M Asara, Lewis C Cantley, Bin Zheng.   

Abstract

BRAF is an oncogenic protein kinase that drives cell growth and proliferation through the MEK-ERK signaling pathway. BRAF inhibitors have demonstrated antitumor efficacy in melanoma therapy but have also been found to be associated with the development of cutaneous squamous cell carcinomas (cSCCs) in certain patients. Here, we report that BRAF is phosphorylated at Ser729 by AMP-activated protein kinase (AMPK), a critical energy sensor. This phosphorylation promotes the association of BRAF with 14-3-3 proteins and disrupts its interaction with the KSR1 scaffolding protein, leading to attenuation of the MEK-ERK signaling. We also show that phosphorylation of BRAF by AMPK impairs keratinocyte cell proliferation and cell-cycle progression. Furthermore, AMPK activation attenuates BRAF inhibitor-induced ERK hyperactivation in keratinocytes and epidermal hyperplasia in mouse skin. Our findings reveal a mechanism for regulating BRAF signaling in response to energy stress and suggest a strategy for preventing the development of cSCCs associated with BRAF-targeted therapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24095280      PMCID: PMC3892895          DOI: 10.1016/j.molcel.2013.08.044

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  48 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

3.  Targeting RAF: trials and tribulations.

Authors:  Julian Downward
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

4.  Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.

Authors:  Jiancheng Hu; Haiyang Yu; Alexandr P Kornev; Jianping Zhao; Erin L Filbert; Susan S Taylor; Andrey S Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-25       Impact factor: 11.205

5.  A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.

Authors:  Damian F Brennan; Arvin C Dar; Nicholas T Hertz; William C H Chao; Alma L Burlingame; Kevan M Shokat; David Barford
Journal:  Nature       Date:  2011-03-27       Impact factor: 49.962

6.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

7.  BRAF targeted therapy changes the treatment paradigm in melanoma.

Authors:  Antoni Ribas; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

Review 8.  RAF inhibition and induction of cutaneous squamous cell carcinoma.

Authors:  Caroline Robert; Jean-Philippe Arnault; Christine Mateus
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

9.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors:  Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal:  Nature       Date:  2010-02-03       Impact factor: 49.962

10.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

View more
  55 in total

1.  BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Authors:  Michael J Vido; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

Review 2.  The pharmacology of nociceptor priming.

Authors:  Ram Kandasamy; Theodore J Price
Journal:  Handb Exp Pharmacol       Date:  2015

3.  A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.

Authors:  Junfeng Xia; Peilin Jia; Katherine E Hutchinson; Kimberly B Dahlman; Douglas Johnson; Jeffrey Sosman; William Pao; Zhongming Zhao
Journal:  Mol Cancer Ther       Date:  2014-04-22       Impact factor: 6.261

4.  Adaptation of HepG2 cells to a steady-state reduction in the content of protein phosphatase 6 (PP6) catalytic subunit.

Authors:  Joan M Boylan; Arthur R Salomon; Umadevi Tantravahi; Philip A Gruppuso
Journal:  Exp Cell Res       Date:  2015-05-18       Impact factor: 3.905

Review 5.  Regulation of RAF protein kinases in ERK signalling.

Authors:  Hugo Lavoie; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05       Impact factor: 94.444

Review 6.  Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain.

Authors:  Theodore J Price; Kufreobong E Inyang
Journal:  Prog Mol Biol Transl Sci       Date:  2015-01-30       Impact factor: 3.622

7.  Loss of AMPKα1 expression is associated with poor survival in melanoma patients.

Authors:  Madhuri Bhandaru; Magdalena Martinka; Gang Li; Anand Rotte
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

8.  Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin.

Authors:  Stephanie Shiers; Grishma Pradhan; Juliet Mwirigi; Galo Mejia; Ayesha Ahmad; Sven Kroener; Theodore Price
Journal:  J Neurosci       Date:  2018-07-20       Impact factor: 6.167

9.  Ca2+-Stimulated AMPK-Dependent Phosphorylation of Exo1 Protects Stressed Replication Forks from Aberrant Resection.

Authors:  Shan Li; Zeno Lavagnino; Delphine Lemacon; Lingzhen Kong; Alessandro Ustione; Xuewen Ng; Yuanya Zhang; Yingchun Wang; Bin Zheng; Helen Piwnica-Worms; Alessandro Vindigni; David W Piston; Zhongsheng You
Journal:  Mol Cell       Date:  2019-04-30       Impact factor: 17.970

Review 10.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.